GSK announced that the FDA has approved the IL-5 inhibitor Nucala (mepolizumab), as an autoinjector and a pre-filled safety syringe, (for use in severe eosinophilic asthma & disease eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/XXGJxLDta7